Cell Therapeutic Compositions - AUTOLUS LIMITED - US12612443B2
Summary
USPTO granted Patent US12612443B2 to AUTOLUS LIMITED on April 28, 2026. The patent covers engineered cells comprising a chimeric antigen receptor (CAR) and signal transduction modifying proteins, including truncated SH2 domain proteins and fusion proteins. The technology relates to cancer treatment applications using modified immune cells.
“The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain;”
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
USPTO granted Patent US12612443B2 to AUTOLUS LIMITED on April 28, 2026. The patent covers cell therapeutic compositions comprising a chimeric antigen receptor (CAR) and a signal transduction modifying protein. The claimed inventions include truncated proteins lacking kinase or phosphatase domains, as well as fusion proteins combining SH2 domains with heterologous domains.
Affected parties in the biotechnology and cell therapy sectors should note this patent when developing similar CAR-based therapeutic technologies. The patent may affect freedom-to-operate assessments for companies working in the chimeric antigen receptor space, particularly those targeting cancer treatment applications using modified immune cells with signal transduction modifiers.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Cell
Grant US12612443B2 Kind: B2 Apr 28, 2026
Assignee
AUTOLUS LIMITED
Inventors
Martin Pulé, Shaun Cordoba, Simon Thomas, Khai Kong
Abstract
The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.
CPC Classifications
C07K 14/7051 C07K 16/2803 C07K 16/2809 C07K 16/2815 C07K 16/2818 C07K 2317/622 C07K 2319/02 C07K 2319/033 A61P 35/00 A61K 40/42 A61K 40/31 A61K 40/11 A61K 2039/5156 A61K 2039/5158 C12N 5/0636 C12N 15/867 C12N 2501/998 C12N 2510/00
Filing Date
2021-11-12
Application No.
17525244
Claims
3
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.